Antiangiogenic therapy in high-risk keratoplasty

Труфанов, С В; Malozhen, S A; Krakhmaleva, D.A.; Surnina, Z.V.; Pivin, Edward; Kasparova, E A

doi:10.17116/oftalma202013604111

Cited by 7 publications

(7 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With careful examination of the contents, we removed 73 case reports/series or single-arm studies, three studies using duplicate samples, and one retrospective case-control study. Finally, we included nine RCTs[ 15 - 23 ] and three NRTs[ 24 - 26 ].…”

Section: Resultsmentioning

confidence: 99%

“…For NRTs, two studies were of moderate risk in the bias due to confounding (D1) due to the lack of baseline information or appropriate analysis to control the confounding[ 25 , 26 ], two trials were of moderate risk in the bias due to missing data (D5) because they did not report the missing data[ 24 , 26 ], and two trials were of serious risk in the bias in the selection of the reported result (D7) because statistical analyses were not conducted in these trials[ 25 , 26 ]. All three NRTs were of low risk in the bias in the selection of participants into the study (D2), bias in the classification of interventions (D3), bias due to deviations from intended interventions (D4), and bias in the measurement of outcomes D6.…”

Section: Resultsmentioning

confidence: 99%

“…All three NRTs were of low risk in the bias in the selection of participants into the study (D2), bias in the classification of interventions (D3), bias due to deviations from intended interventions (D4), and bias in the measurement of outcomes D6. For the overall risk, one NRT had a moderate risk[ 24 ], whereas the other two NRTs had a serious risk[ 25 , 26 ].…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy and safety of anti-vascular endothelial growth factor agents on corneal neovascularization: A meta-analysis

Lai,

Loh,

Chiou

et al. 2023

World J Clin Cases

View full text Add to dashboard Cite

Rehabilitation of lower limb amputation in developing countries is quite challenging. Though there are basic to highly advanced prostheses available in India, the set-up is still facing difficulties in developing countries. Prosthetic management is difficult due to lack of availability of prostheses and reduced affordability among low income populations. In this review we highlighted the lower limb amputation and prosthetic rehabilitation status in India. Currently, India is advancing well in the rehabilitation field, but further studies are required to provide more evidence and recommendation.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety of anti-vascular endothelial growth factor agents on corneal neovascularization: A meta-analysis

Lai,

Loh,

Chiou

et al. 2023

World J Clin Cases

View full text Add to dashboard Cite

show abstract

“…Additionally, clinical studies have suggested that anti-VEGF drugs, including bevacizumab and aflibercept, could be a safe and efficient treatment alternative to improve the outcomes of corneal transplantation in patients. Previous reports have demonstrated that anti-VEGF therapy improved graft survival in patients who have undergone penetrating keratoplasty [135][136][137]. However, when considering the current immunotherapies for corneal transplantation, the diverse experimental methods in animal models and the lack of clinical trials contribute to the disconnection between basic research and clinical practice.…”

Section: Discussionmentioning

confidence: 99%

Role of Immune Cell Diversity and Heterogeneity in Corneal Graft Survival: A Systematic Review and Meta-Analysis

Zhu

Inomata

Zazzo

et al. 2021

JCM

View full text Add to dashboard Cite

Corneal transplantation is one of the most successful forms of solid organ transplantation; however, immune rejection is still a major cause of corneal graft failure. Both innate and adaptive immunity play a significant role in allograft tolerance. Therefore, immune cells, cytokines, and signal-transduction pathways are critical therapeutic targets. In this analysis, we aimed to review the current literature on various immunotherapeutic approaches for corneal-allograft rejection using the PubMed, EMBASE, Web of Science, Cochrane, and China National Knowledge Infrastructure. Retrievable data for meta-analysis were screened and assessed. The review, which evaluated multiple immunotherapeutic approaches to prevent corneal allograft rejection, showed extensive involvement of innate and adaptive immunity components. Understanding the contribution of this immune diversity to the ocular surface is critical for ensuring corneal allograft survival.

show abstract

“…[29], [30] Coherently to this, recent literature reported that subconjunctival administration of A ibercept as a stand-alone measure and in combination with laser coagulation of ingrowing vessels may increase the chances of transparent transplant acceptance in high-risk keratoplasty. [31] An explanation for this positive outcome lays in the downregulating effect of anti-VEGFs towards in ammation and in the vasoconstrictive local effect that they elicite. Once again, it is critical to emphasize that the most important prognosticator of graft success is the status of the recipient bed in which the corneal graft is placed: in amed host beds are extremely prone to rejection and the removal of this stimulus is of utmost importance.…”

Section: Discussionmentioning

confidence: 99%

Role of pre-transplant corneal injective anti VEGF treatment in high risk transplantation corneas

Fasciani

Crincoli

Mosca

et al. 2021

Preprint

View full text Add to dashboard Cite

Background In “high-risk” corneal graft recipients, like those with neovascularization of the cornea, the failure rate can exceed 35% at three years, the main cause being graft rejection. The main purpose of the study is to demonstrate the efficacy of pre-transplant Bevacizumab corneal injection in long term lowering of the prevalence of graft failure and rejection in high risk corneal transplantations. Methods This retrospective single-centre case-control study analyzed 37 eyes with significant corneal neovascularization and eligible for corneal transplantation at baseline. One group (BT group) included patients who were treated with a 3 months preoperative cycle of subconjunctival and/or intrastromal 5 mg/0.2 ml Bevacizumab injected at the limbus with a 27 G needle. The control group (NT group) didn’t receive the preoperative treatment. The main outcome was the prevalence of graft failures and rejections during the follow up period. Secondary outcomes included the prevalence of adverse events and the prevalence of patients who avoided corneal transplantation due to the treatment. Results BT group included 24 eyes with a follow up duration of 61.2 ± 24 months. Eight patients (33.3%) avoided transplant surgery after the injection. In the BT group 5 cases of graft failure (20.8%), 1 of which due to graft rejection (4%), occurred during the follow up. The NT group registered 6 cases (46.1%) of immune rejection of the graft and no additional graft failures from other causes. Conclusions Pre-transplant bevacizumab corneal injections are a safe and effective method to prevent graft rejection in neovascularized corneas.

show abstract

Antiangiogenic therapy in high-risk keratoplasty

Cited by 7 publications

References 15 publications

Efficacy and safety of anti-vascular endothelial growth factor agents on corneal neovascularization: A meta-analysis

Efficacy and safety of anti-vascular endothelial growth factor agents on corneal neovascularization: A meta-analysis

Role of Immune Cell Diversity and Heterogeneity in Corneal Graft Survival: A Systematic Review and Meta-Analysis

Role of pre-transplant corneal injective anti VEGF treatment in high risk transplantation corneas

Contact Info

Product

Resources

About